Skip to content
DraconiticResearch
Search Sources API
220,782 studies31 sourcesUpdated 4 min ago
Peer-reviewedCC BYHealth science reports

Low Level Viremia in Early HIV RNA Kinetics in Naïve People Living With HIV Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir/Abacavir/Lamivudine: An Observational Multicenter Retrospective Study.

  • Nicola Bonadiman1
  • Monica Basso1
  • Maria Cristina Rossi2
  • Mario Giobbia2
  • Gloria Tomarchio1
  • Gaia Doro1
  • Carla Casarin1
  • Pietro Luigi Rocco1
  • Francesca Cattelan3
  • Giuliana Battagin4
  • Saverio G Parisi1,2
4 affiliations
  1. 1Department of Molecular Medicine University of Padova Padova Italy.
  2. 2Infectious Disease Unit Treviso Hospital Treviso Italy.
  3. 3Infectious Diseases Unit, dell'Angelo Hospital Venezia Italy.
  4. 4Infectious Diseases Unit, Vicenza Hospital Vicenza Italy.
Read full textPDFDOICite

Abstract

Integrase inhibitors have a pivotal role in antiviral therapyA quarter of PLWH had LLV after 3 months of treatmentPLWH with LLV had immunological parameters lower than PLWH with virological suppression but comparable to those with partial response.

Related

  1. Bictegravir/emtricitabine/tenofovir alafenamide for HIV: a meta-analysis of efficacy across treatment-naïve and experienced populations and comparative effectiveness versus dolutegravir/lamivudine
    Mingxia Cheng, Aiwen Wang, Qingshuang Zhu +6
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  2. A real-world pharmacovigilance study of FDA adverse event reporting system events for bictegravir/emtricitabine/tenofovir alafenamide
    Ying Liu, Leidan Zhang, Xin Li +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMCEurope PMCPMC
  3. A Highly Sensitive and Specific Rapid Lateral Flow Assay for the HIV Integrase Strand Transfer Inhibitors Bictegravir, Cabotegravir, and Dolutegravir.
    Xierong Wei, Ae S Youngpairoj, Richard Haaland +6
    AIDS research and treatmentPeer-reviewedCC BYFull textInfectious diseaseEurope PMC
  4. Comparative safety of dolutegravir-based and second-line antiretroviral therapy on adverse birth outcomes: a retrospective cohort study of HIV-positive women in Nigeria.
    Erick Wesley Hedima, Abubakar Ibrahim Aliyu
    Maternal health, neonatology and perinatologyPeer-reviewedCC BY-NC-NDFull textInfectious diseaseEurope PMC
  5. Season-adjusted longitudinal changes in serum 25-hydroxyvitamin D during pegylated interferon add-on to ongoing tenofovir alafenamide therapy in chronic hepatitis B: a real-world cohort study
    Ning Han, Huan Liu, Xia Zhu
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{bonadiman2026level,
  title = {{Low Level Viremia in Early HIV RNA Kinetics in Naïve People Living With HIV Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir/Abacavir/Lamivudine: An Observational Multicenter Retrospective Study.}},
  author = {Nicola Bonadiman and Monica Basso and Maria Cristina Rossi and Mario Giobbia and Gloria Tomarchio and Gaia Doro and Carla Casarin and Pietro Luigi Rocco and Francesca Cattelan and Giuliana Battagin and Saverio G Parisi},
  journal = {Health science reports},
  year = {2026},
  month = nov,
  doi = {10.1002/hsr2.73493},
  url = {https://europepmc.org/article/MED/43011739},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Low Level Viremia in Early HIV RNA Kinetics in Naïve People Living With HIV Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir/Abacavir/Lamivudine: An Observational Multicenter Retrospective Study.
AU  - Nicola Bonadiman
AU  - Monica Basso
AU  - Maria Cristina Rossi
AU  - Mario Giobbia
AU  - Gloria Tomarchio
AU  - Gaia Doro
AU  - Carla Casarin
AU  - Pietro Luigi Rocco
AU  - Francesca Cattelan
AU  - Giuliana Battagin
AU  - Saverio G Parisi
PY  - 2026
DA  - 2026/11/10
JO  - Health science reports
DO  - 10.1002/hsr2.73493
UR  - https://europepmc.org/article/MED/43011739
AB  - Integrase inhibitors have a pivotal role in antiviral therapyA quarter of PLWH had LLV after 3 months of treatmentPLWH with LLV had immunological parameters lower than PLWH with virological suppression but comparable to those with partial response.
SN  - 2398-8835
ER  -